Skip to content
CancerIndex

Publication

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.

Authors not recorded

Mol Cancer Ther2009PMID 19671763PMC3346953stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (7)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 7

Curated evidence

Evidence citing this paper (3)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
19671763
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
BRAF V600E1
DasatinibMelanomaPredictiveDDoes Not Support Sensitivity Response2submitted
EID3759

In an in vitro study, a melanoma cell line, A375 (Amelanotic melanoma), expressing the BRAF V600E mutation was associated with resistance to dasatinib treatment, comparable to melanoma MEWO cells expr… (full text at CIViC)

PMID 19671763 · Woodman et al., 2009 · Open in CIViC

civic
KIT L576P2
DasatinibMelanomaPredictiveDSupports Sensitivity Response3accepted
EID42

The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding… (full text at CIViC)

PMID 19671763 · Woodman et al., 2009 · Open in CIViC

civic
Imatinib + Nilotinib + SorafenibSubstitutesMelanomaPredictiveDSupports Resistance3accepted
EID34

The melanoma cell line WM3211 (derived from an acral lentiginous melanoma), which harbors the L576P mutation, is not sensitive to imatinib, nilotinib, and sorafenib. Molecular modeling indicated the L… (full text at CIViC)

PMID 19671763 · Woodman et al., 2009 · Open in CIViC

civic